<DOC>
	<DOC>NCT00637988</DOC>
	<brief_summary>This study evaluates PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue. All patients will have a baseline endoscopy with multiple biopsies. The patients will then be receive four dosing regimens (esomeprazole, esomeprazole and aspirin, esomeprazole and rofecoxib, or rofecoxib alone) consecutively each for a 10 day dosing period, whilst undergoing further follow up endoscopies and multiple biopsies.</brief_summary>
	<brief_title>Barrett's Esophagus - 315 - 3 Way Cross Over</brief_title>
	<detailed_description />
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>A biopsyproven diagnosis of Barrett's esophagus segment length greater than 2cm with no dysplasia or adenocarcinoma. Clinically normal laboratory results and physical findings at screening. A history of esophageal, gastric or duodenal surgery, including antireflux surgery or endoscopic antireflux procedures, except for simple closure of an ulcer. Evidence of the following diseases or conditions: Barrett's esophagus less than or greater than 2cm that is positive for high grade dysplasia or adenocarcinoma Signs and symptoms of gastric outlet obstruction Active peptic ulcer disease severe liver disease Pancreatitis Malabsorption Active inflammatory bowel disease Severe pulmonary, cardiovascular or renal disease Impaired renal function or abnormal urine sediment on repeated examinations esophageal stricture or active, severe esophagitis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Barrett's Esophagus</keyword>
	<keyword>Nexium</keyword>
</DOC>